Actinium Pharmaceuticals reported new analyses from Phase 3 SIERRA trial

Actinium Pharmaceuticals reported new analyses from the Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings Transplantation & Cellular Therapy, TCT, Meetings of ASTCT. The presentations reported unprecedented 100% access to potentially curative bone marrow transplant and engraftment in evaluable patients with active relapsed or refractory acute myeloid leukemia and improved long-term survival outcomes greater than 2 years in patients age 65 or older. Patients with r/r AML age 65 and older who also have multiple comorbidities and high-risk cytogenetics have a poor prognosis are seldom offered BMT in current practice due to poor tolerance to induction and conditioning regimens and dismal outcomes. The SIERRA results presented at TCT demonstrate Iomab-B’s ability to overcome multiple high-risk features including a TP53 genetic mutation, advanced age and treatment resistant disease. The two oral presentations at this year’s TCT mark a total of ten oral presentations of the SIERRA results at various leading transplant, hematology and nuclear medicine conferences in the USA and Europe.